Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT – Get Free Report) have been assigned a consensus rating of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $41.50.
A number of brokerages recently commented on SGMT. SVB Leerink assumed coverage on Sagimet Biosciences in a research note on Monday, March 25th. They set an “outperform” rating and a $26.00 price objective for the company. JMP Securities dropped their target price on shares of Sagimet Biosciences from $47.00 to $46.00 and set a “market outperform” rating on the stock in a report on Wednesday, February 7th. The Goldman Sachs Group reduced their target price on shares of Sagimet Biosciences from $37.00 to $27.00 and set a “buy” rating for the company in a research note on Tuesday, March 26th. Finally, Leerink Partnrs reissued an “outperform” rating on shares of Sagimet Biosciences in a research note on Monday, March 25th.
Read Our Latest Stock Report on SGMT
Insider Buying and Selling
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the stock. Victory Capital Management Inc. boosted its holdings in shares of Sagimet Biosciences by 215.0% in the 4th quarter. Victory Capital Management Inc. now owns 56,570 shares of the company’s stock valued at $307,000 after buying an additional 38,610 shares during the last quarter. Federated Hermes Inc. lifted its stake in Sagimet Biosciences by 24.7% in the fourth quarter. Federated Hermes Inc. now owns 97,276 shares of the company’s stock valued at $527,000 after acquiring an additional 19,276 shares during the last quarter. RTW Investments LP acquired a new position in shares of Sagimet Biosciences during the 3rd quarter worth about $3,522,000. Rock Springs Capital Management LP acquired a new position in shares of Sagimet Biosciences during the 3rd quarter worth about $6,498,000. Finally, Dumac Inc. bought a new stake in shares of Sagimet Biosciences in the 3rd quarter valued at about $1,796,000. 87.86% of the stock is currently owned by institutional investors.
Sagimet Biosciences Stock Up 6.2 %
SGMT opened at $4.28 on Friday. The company has a fifty day moving average price of $5.55 and a two-hundred day moving average price of $5.74. Sagimet Biosciences has a 52 week low of $2.13 and a 52 week high of $20.71.
Sagimet Biosciences Company Profile
Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.
See Also
- Five stocks we like better than Sagimet Biosciences
- With Risk Tolerance, One Size Does Not Fit All
- Charles Schwab Fortifies its Uptrend on EPS Beat
- ETF Screener: Uses and Step-by-Step Guide
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Dividend Payout Ratio Calculator
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Sagimet Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagimet Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.